UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 911

Sortiert nach

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

Journal of clinical oncology, 2009-11, Vol.27 (33), p.5529-5537

2009

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Journal of clinical oncology, 2009-04, Vol.27 (12), p.1999-2006

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Breast cancer research and treatment, 2015-01, Vol.149 (1), p.171-179

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials

British journal of cancer, 2016-12, Vol.115 (12), p.1520-1529

2016

Link zum Volltext

Verfügbarkeit prüfen

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer

British journal of cancer, 2017-05, Vol.116 (11), p.1462-1469

2017

Link zum Volltext

Verfügbarkeit prüfen

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Breast cancer research and treatment, 2012-04, Vol.132 (3), p.863-870

2012

Link zum Volltext

Verfügbarkeit prüfen

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

BMC cancer, 2014-08, Vol.14 (1), p.624-624, Article 624

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of SPARC expression level on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: A pooled analysis from prospective clinical and translational trials

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15264-e15264

2015

Link zum Volltext

Verfügbarkeit prüfen

Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.504-504

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized, open-label study of YM155 (sepantronium bromide) plus docetaxel versus docetaxel alone as first-line treatment for HER2 negative metastatic breast cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.548-548

2013

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.557-557

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS1141-TPS1141

2013

Link zum Volltext

Verfügbarkeit prüfen

Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104)

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.189-189

2013

Link zum Volltext

Verfügbarkeit prüfen

Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.11043-11043

2013

Link zum Volltext

Verfügbarkeit prüfen

Fish oil preparations rich in docosahexaenoic acid modify platelet responsiveness to prostaglandin-endoperoxide/thromboxane A2 receptor agonists

Biochemical pharmacology, 1993-07, Vol.46 (2), p.245-249

1993

Link zum Volltext

Verfügbarkeit prüfen

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.552-552

2012

Link zum Volltext

Verfügbarkeit prüfen

Decreased Essential Antioxidants and Increased Lipid Hydroperoxides Following High-Dose Radiochemotherapy

Free radical research, 1989-01, Vol.7 (3-6), p.227-232

1989

Link zum Volltext

Verfügbarkeit prüfen

Lipid peroxidation in erythrocytes

Chemistry and physics of lipids, 1987-11, Vol.45 (2), p.251-268

1987

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer

Anti-cancer drugs, 1997-04, Vol.8 (4), p.396-399

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 911

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(695)
Mit Volltextzugriff
(817)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(892)
Japanisch
(122)
Deutsch
(15)
Russisch
(3)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(559)
Life Sciences & Biomedicine
(457)
Humans
(391)
Male
(242)
Female
(227)
Middle Aged
(167)
Biological And Medical Sciences
(150)
Animals
(138)
Aged
(128)
Medical Sciences
(124)
Adult
(118)
Physical Sciences
(65)
Treatment Outcome
(62)
Biochemistry & Molecular Biology
(59)
Mice
(59)
Neurosciences & Neurology
(55)
Oncology
(52)
Cardiovascular System & Cardiology
(50)
Science & Technology - Other Topics
(48)
Aged, 80 And Over
(47)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia

Impact of SPARC expression level on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: A pooled analysis from prospective clinical and translational trials

Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer

Phase II randomized, open-label study of YM155 (sepantronium bromide) plus docetaxel versus docetaxel alone as first-line treatment for HER2 negative metastatic breast cancer

Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial

A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69

Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104)

Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial

Fish oil preparations rich in docosahexaenoic acid modify platelet responsiveness to prostaglandin-endoperoxide/thromboxane A2 receptor agonists

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial

Decreased Essential Antioxidants and Increased Lipid Hydroperoxides Following High-Dose Radiochemotherapy

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone

Lipid peroxidation in erythrocytes

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone

A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer

Suchergebnisse filtern